Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.49 USD
-0.03 (-5.14%)
Updated Apr 18, 2024 03:37 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Panbela Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 26 | 34 | 10 | 6 | 4 |
Income After Depreciation & Amortization | -26 | -34 | -10 | -6 | -4 |
Non-Operating Income | 1 | -1 | -1 | 1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 2 |
Pretax Income | -25 | -35 | -11 | -5 | -7 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -25 | -35 | -10 | -5 | -6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -25 | -35 | -10 | -5 | -6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -26 | -34 | -10 | -6 | -2 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 2 |
Income After Depreciation & Amortization | -26 | -34 | -10 | -6 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.11 | 0.00 | 0.00 | 0.00 | NA |
Diluted EPS Before Non-Recurring Items | -316.52 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -316.52 | NA | NA | NA | NA |
Fiscal Year end for Panbela Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.06 | 7.85 | 5.87 | 4.86 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.06 | -7.85 | -5.87 | -4.86 |
Non-Operating Income | NA | 0.63 | 0.07 | -0.03 | -0.15 |
Interest Expense | NA | 0.07 | 0.07 | 0.07 | 0.10 |
Pretax Income | NA | -6.51 | -7.85 | -5.98 | -5.11 |
Income Taxes | NA | -0.02 | -0.02 | -0.15 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -6.49 | -7.83 | -5.83 | -5.11 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -6.49 | -7.83 | -5.83 | -5.11 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 0.24 | 0.15 | 0.04 | 0.01 |
Diluted EPS Before Non-Recurring Items | NA | -65.90 | -53.80 | -159.00 | -390.39 |
Diluted Net EPS (GAAP) | NA | 286.67 | -53.80 | -159.00 | -390.39 |